High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

Serum-free light chain (SFLC) levels are useful for diagnosing nonsecretory myeloma and monitoring response in light-chain–only disease, especially in the presence of renal failure. As part of a tandem autotransplantation trial for newly diagnosed multiple myeloma, SFLC levels were measured at basel...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: van Rhee, Frits, Bolejack, Vanessa, Hollmig, Klaus, Pineda-Roman, Mauricio, Anaissie, Elias, Epstein, Joshua, Shaughnessy, John D., Zangari, Maurizio, Tricot, Guido, Mohiuddin, Abid, Alsayed, Yazan, Woods, Gail, Crowley, John, Barlogie, Bart
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2007
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC1924775/
https://ncbi.nlm.nih.gov/pubmed/17416735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-01-067728
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia